Loading…
Second Look at Drug Patents Act of 2020
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Second Look at Drug Patents Act of 2020 This bill imposes additional patent reporting requirements on the manufacturers of certain drugs approved by the Federal Drug Administration.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2020 · third_quarter · Copyright/Patent/Trademark
Patent Settlements. Patent Abuse. BPCIA Patent Dance. Inter Partes Review. Government patent use law in regards to Section 1498 of statute codified at 28 USC Section 1498(a). H.R.4850/S.659: Biologic Patent Transparency Act. H.R.3666: STRONGER Patents Act of 2019. S.4253: Second Look at Drug Patents Act of 2020.
Client expense: $940,000 · Firm income: Not reported
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office